证券代码：688520 证券简称：神州细胞 公告编号：2025-022 北京神州细胞生物技术集团股份公司 第三届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京神州细胞生物技术集团股份公司（以下简称"公司"）第三届董事会第二 次会议于 2025 年 6 月 5 日在公司会议室以现场及通讯方式召开，本次会议的通 知及相关材料于 2025 年 5 月 30 日送达全体董事。本次会议应出席董事 7 人，实 际到会董事 7 人。本次会议由董事长谢良志先生主持，会议的召集和召开程序符 合《中华人民共和国公司法》《北京神州细胞生物技术集团股份公司章程》（以 下简称"《公司章程》"）以及其他有关法律法规、规范性文件的规定。 二、董事会会议审议情况 经与会董事充分讨论，会议以投票表决方式审议通过了如下议案： （一）审议通过《关于公司符合向特定对象发行 A 股股票条件的议案》 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券 发行注册管理办法》等有关法律法规和规范性文件 ...

证券代码：688520 证券简称：神州细胞 公告编号：2025-030 北京神州细胞生物技术集团股份公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 股东会召开日期：2025年6月23日 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 召开地点：北京市北京经济技术开发区科创七街 31 号院研发楼会议室 （五） 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 6 月 23 日 至2025 年 6 月 23 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联网 投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京神州细胞生物技术集团股份公司（以下简称"公司"或"神州细胞"） 于2025年6月5日召开第三届董事会第二次会议，审议通过了公司2025年度向特定 对象发行A股股票（以下简称"本次发行"）的相关议案。具体内容详见公司在 上海证券交易所网站（www.sse.com.cn）披露的相关公告。敬请广大投资者注意 查阅。 公司控股股东拉萨爱力克投资咨询有限公司作为本次发行的发行对象，就本 次发行相关事宜出具《关于本次发行相关事宜的承诺函》，具体内容如下： 名下之日）后6个月内，本公司不减持神州细胞股份，也不存在减持神州细胞股 份的计划； 办法》等法律法规、交易所的相关规定进行减持并履行权益变动涉及的信息披露 义务； 部归神州细胞所有； 证券代码：688520 证券简称：神州细胞 公告编号：2025-029 关于拉萨爱力克投资咨询有限公司就 本次发行相关事宜出具承诺函的公告 本次发行完成后，本公司取得的神州细胞本次发行的股票，因神州细胞分配 股票股利、资本公积转增股本等情形所衍生取得的 ...

Core Viewpoint - The company plans to issue A-shares to specific investors in 2025, which may dilute immediate returns for existing shareholders, but it has proposed measures to mitigate this impact [1][5][9]. Impact on Earnings Per Share - The issuance is expected to increase the total share capital from 44,533.57 million shares to 48,986.93 million shares [2]. - In a scenario where the net profit attributable to shareholders decreases by 10%, the diluted earnings per share (EPS) would drop from 0.24 to 0.18 yuan [2]. - If the net profit remains flat compared to 2024, the diluted EPS would decrease from 0.24 to 0.20 yuan [4]. - In a scenario where the net profit increases by 10%, the diluted EPS would slightly decrease from 0.24 to 0.23 yuan [4]. Necessity and Reasonableness of the Issuance - The issuance aims to supplement working capital to support business growth, especially in the high-investment biopharmaceutical and vaccine sectors [5][6]. - Continuous R&D investment is crucial for maintaining competitive advantages, and the funds will support ongoing innovation [5][6]. - The issuance will help reduce operational and financial risks by improving the company's financial structure and liquidity [6]. Use of Proceeds - All proceeds from the issuance will be used to enhance working capital, accelerating the R&D process and enriching the product pipeline [6][7]. Measures to Mitigate Dilution of Immediate Returns - The company will manage the raised funds strictly according to legal regulations to ensure proper usage [7][8]. - A detailed plan for the use of funds will be implemented to enhance business development and market competitiveness [7]. - The company will improve governance and internal controls to protect investor interests and ensure efficient fund utilization [8]. - A profit distribution policy will be established to optimize returns for investors, with a commitment to cash dividends when conditions allow [8][9]. Commitments from Management - The board of directors and senior management have committed to ensuring the effectiveness of the proposed measures to mitigate dilution [9][10]. - The actual controller and major shareholders have also made commitments to not interfere with the company's management and to protect shareholder interests [10][11].

北京神州细胞生物技术集团股份公司 未来三年（2025 年-2027 年）股东分红回报规划 为进一步规范和完善北京神州细胞生物技术集团股份公司（以下简称"公 司"）的利润分配政策，建立科学、持续、稳定的股东回报机制，维护中小股东 的合法权益，根据中国证券监督管理委员会《上市公司监管指引第 3 号—上市公 司现金分红（2025 年修订）》和《北京神州细胞生物技术集团股份公司章程》 （以 下简称"《公司章程》"）等相关文件规定，结合公司实际情况，公司董事会制定 了《北京神州细胞生物技术集团股份公司未来三年（2025 年-2027 年）股东分红 回报规划》，具体内容如下： 一、公司制定本规划考虑的因素 公司着眼于长远、可持续的发展，综合考虑公司实际情况、发展战略规划以 及行业发展趋势，建立对投资者科学、持续、稳定的回报规划与机制，从而对利 润分配做出制度性安排，以保证利润分配政策的连续性和稳定性。 二、本规划的制定原则 本规划的制定应符合《公司章程》有关利润分配的相关条款，重视对股东的 合理投资回报并兼顾公司当年的实际经营情况和可持续发展，在充分考虑股东利 益的基础上处理公司的短期利益及长远发展的关系，确定合理的利润 ...

Summary of Key Points Core Viewpoint The report details the fundraising activities and the utilization of proceeds by Beijing Shenzhou Cell Biotechnology Group Co., Ltd., highlighting the total amounts raised, the allocation of funds, and the status of various projects as of March 31, 2025. Group 1: Fundraising Overview - The company raised a total of RMB 1,282 million through its initial public offering (IPO) at a price of RMB 25.64 per share, with a net amount of RMB 1,201 million after deducting underwriting fees [1][2]. - In 2021, the company raised RMB 483.3 million through a private placement of 10 million shares at RMB 48.33 per share, resulting in a net amount of RMB 471.4 million after fees [1][2]. Group 2: Fund Utilization - As of March 31, 2025, the total amount utilized from the IPO proceeds was RMB 1,229.9 million, with no remaining balance [2][3]. - The funds raised in 2021 were fully utilized, with RMB 472.6 million allocated to various projects [2][3]. Group 3: Changes in Fund Allocation - The company approved changes to the allocation of funds from the IPO, allowing for the permanent supplementation of working capital with surplus funds from certain projects [2][3]. - Specific projects, such as clinical research for cancer treatments, saw adjustments in funding amounts, with a total of RMB 14.3 million reduced from certain clinical projects [2][3]. Group 4: Cash Management of Idle Funds - The company has engaged in cash management for idle funds, allowing for investments in safe, liquid products, with a maximum of RMB 260 million allocated for such investments [4][5]. - As of March 31, 2025, there were no remaining balances from idle funds for both the IPO and the 2021 private placement [5][6]. Group 5: Project Performance and Reporting - The company did not make any commitments regarding the performance of projects funded by the raised capital, thus no specific performance metrics are applicable [6][7]. - The actual investment amounts exceeded the committed amounts due to the inclusion of interest income and bank investment returns [7].

Core Viewpoint - The company, Beijing Shenzhou Cell Biotechnology Group Co., Ltd., is focused on raising funds for its operations in the biotechnology sector, specifically in the development of innovative biopharmaceuticals targeting various diseases, which aligns with the technology innovation field [1][4]. Company Overview - Shenzhou Cell is dedicated to developing biopharmaceuticals with differentiated competitive advantages, focusing on areas such as malignant tumors, autoimmune diseases, infectious diseases, and genetic disorders [1]. - The company has established a high-efficiency, high-throughput technology platform covering the entire chain of biopharmaceutical research and production, having developed a diverse pipeline of monoclonal antibodies, recombinant proteins, and innovative vaccines [1]. Industry Characteristics - The pharmaceutical industry is characterized by high investment and technology requirements, particularly in the biopharmaceutical sector, which involves extensive clinical research, trials, and regulatory approvals [2]. - The industry is classified as technology-intensive, capital-intensive, and talent-intensive, necessitating significant funding and skilled personnel [2]. Fundraising Plan - The total amount to be raised through the issuance of A-shares is not to exceed 900 million yuan, with all proceeds intended to supplement working capital after deducting issuance costs [2][4]. - The funds will alleviate the pressure on the company's working capital needs, supporting sustainable development and business expansion [2][3]. Use of Funds - The funds will be used to enhance operational capabilities, support ongoing research and development, and improve the company's core competitiveness [3][5]. - Historical R&D investments were significant, with amounts of 973 million yuan, 1.217 billion yuan, and 936 million yuan planned for 2022, 2023, and 2024 respectively, indicating a strong commitment to innovation [3]. Compliance and Governance - The fundraising plan complies with relevant laws and regulations, enhancing the company's capital strength and market competitiveness [4]. - The company has established a modern corporate governance structure and internal control environment to manage and utilize the raised funds effectively [4]. Conclusion - The fundraising is aligned with the company's focus on technology innovation, aiming to enhance its R&D capabilities and reinforce its position in the biopharmaceutical industry [5].

证券代码：688520 证券简称：神州细胞 公告编号：2025-025 北京神州细胞生物技术集团股份公司 关于与特定对象签署附条件生效的股份认购协议暨 关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京神州细胞生物技术集团股份公司（以下简称"公司"）拟向特定对象发 行不超过25,000,000股（含）人民币普通股（A股）股票（以下简称"本次发行"）， 募集资金总额不超过90,000.00万元（含）人民币。本次发行的发行对象为公司控 股股东拉萨爱力克投资咨询有限公司（以下简称"拉萨爱力克"），拉萨爱力克 以现金方式认购本次发行的股票，拟认购金额不超过人民币90,000.00万元（含本 数）。最终认购本次发行的股数为实际认购金额除以认购价格，对认购股份数量 不足1股的尾数作舍去处理。 截至本公告日，拉萨爱力克为公司控股股东，根据《上海证券交易所科创板 股票上市规则》等相关规定，拉萨爱力克认购本次发行的股票构成关联交易，本 次关联交易不构成重大资产重组。 本次发行的相关议案已经公司第三届董事会第 ...

Group 1 - The company plans to raise a total of no more than 900 million yuan through a private placement of A-shares, with all proceeds intended to supplement working capital after deducting issuance costs [1] - The necessity of the fundraising is highlighted by the company's rapid business expansion, with revenue growth rates of 661.33%, 84.46%, and 33.13% in recent years, indicating a strong demand for operational funds in the high-tech biopharmaceutical and vaccine sectors [1][2] - The company has a significant historical investment in R&D, with expenditures of 973 million yuan, 1.217 billion yuan, and 936 million yuan for the years 2022, 2023, and 2024 respectively, and cumulative losses reaching 3.76 billion yuan as of March 31, 2025 [2] Group 2 - The issuance of new shares is expected to enhance the company's financial strength, reduce the debt-to-asset ratio, and improve liquidity, thereby increasing operational safety and asset fluidity [2][3] - The company has established a modern corporate governance structure and a clear management framework for the use of raised funds, ensuring compliance with relevant laws and regulations [3] - Following the completion of the issuance, both total assets and net assets will increase, further improving the company's financial condition and risk resistance capabilities [4]

证券代码：688520 证券简称：神州细胞 北京神州细胞生物技术集团股份公司 （北京市北京经济技术开发区科创七街 31 号院 5 号楼 307） 2025 年度向特定对象发行 A 股股票预案 二〇二五年六月 北京神州细胞生物技术集团股份公司 2025 年度向特定对象发行 A 股股票预案 公司声明 1、公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不存 在虚假记载、误导性陈述或重大遗漏。 2、本预案按照《上市公司证券发行注册管理办法》等法规及规范性文件的 要求编制。 3、本次向特定对象发行 A 股股票完成后，公司经营与收益的变化由公司自 行负责；因本次向特定对象发行 A 股股票引致的投资风险，由投资者自行负责。 4、本预案是公司董事会对本次向特定对象发行 A 股股票的说明，任何与之 相反的声明均属不实陈述。 5、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 6、本预案所述事项并不代表审批机关对于本次向特定对象发行 A 股股票相 关事项的实质性判断、确认、批准或核准，本预案所述本次向特定对象发行 A 股股票相关事项的生效和完成尚待公司股东会审议通过、上海证券交易所审核 ...